MARKET

ZYNE

ZYNE

Zynerba Pharmace
NASDAQ
0.3100
-0.0190
-5.78%
Closed 19:58 05/30 EDT
OPEN
0.3310
PREV CLOSE
0.3290
HIGH
0.3700
LOW
0.3100
VOLUME
681.86K
TURNOVER
--
52 WEEK HIGH
1.600
52 WEEK LOW
0.3000
MARKET CAP
16.63M
P/E (TTM)
-0.3769
1D
5D
1M
3M
1Y
5Y
Zynerba Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 17/895,008 Titled "Treatment Of Fragile X Syndrome With Cannabidiol"
Benzinga · 16h ago
SNDL, Invitae among additions to Russell microcap; Inovio, Bionano among deletions
Seeking Alpha · 6d ago
Analysts Offer Insights on Healthcare Companies: Zynerba Pharmaceuticals (ZYNE) and COMPASS Pathways (CMPS)
TipRanks · 05/15 18:30
Zynerba Pharmaceuticals GAAP EPS of -$0.21 misses by $0.02
Seeking Alpha · 05/15 13:22
Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
Benzinga · 05/15 12:46
BRIEF-Zynerba Pharmaceuticals Inc Intends To Seek Approval Of Reverse Stock Split At Annual Meeting
Reuters · 05/15 11:41
Zynerba Pharmaceuticals Q1 EPS $(0.21) Misses $(0.19) Estimate; $44.4M In Cash And Cash Equivalents, With Cash Runway To Mid-year 2024
Benzinga · 05/15 11:28
BRIEF-Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results 
Reuters · 05/15 11:09
More
About ZYNE
Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.